deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.
Armed with $3 million in cash and cleared from bankruptcy,
deCODE genetics Inc. has re-emerged with a streamlined,
diagnostics-oriented business model. In the near term, privately
held deCODE genetics EHF expects to
offer its genomics discovery capabilities on a service basis to
partners seeking to develop gene-based diagnostics and otherwise
use genetic information for assessing disease risk and managing
therapy.
deCODE was revitalized in January by Saga Investments LLC, a consortium formed by Polaris Ventures and ARCH Venture Partners, original...
